Cargando…
An Australian Real-World Study of Treatment Persistence of Ustekinumab in Crohn’s Disease
INTRODUCTION: Real-world treatment persistence to ustekinumab for Crohn’s disease (CD) was studied using Australian Pharmaceutical Benefits Scheme (PBS) data. Demographic and treatment pattern characteristics were also investigated. METHODS: Our retrospective cohort analysis included PBS 10% sample...
Autores principales: | Chien, Tzu Hsiang, Puig, Andrea, Khuong, Thang, Kouhkamari, Mahsa H, Che, Samuel, Huang, Tom Hsun-Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215905/ https://www.ncbi.nlm.nih.gov/pubmed/34163137 http://dx.doi.org/10.2147/BTT.S310076 |
Ejemplares similares
-
Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022) -
Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
por: Hoffmann, Peter, et al.
Publicado: (2019) -
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020) -
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
por: Chaparro, María, et al.
Publicado: (2022) -
Ustekinumab in Crohn's disease: Real‐world outcomes from the Sicilian network for inflammatory bowel diseases
por: Viola, Anna, et al.
Publicado: (2021)